Crown Laboratories Acquires Revance Therapeutics, Expanding Aesthetic Portfolio
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The deal expands Crown’s presence in the aesthetics market, bringing Daxxify and the RHA Collection into its portfolio.
The ready-to-use liquid botulinum toxin treatment requires no reconstitution. Phase III trials showed improvements in frown lines, with some patients maintaining results for up to six months.